ZA200906802B - Probiotic bifidobacterium strains - Google Patents

Probiotic bifidobacterium strains

Info

Publication number
ZA200906802B
ZA200906802B ZA200906802A ZA200906802A ZA200906802B ZA 200906802 B ZA200906802 B ZA 200906802B ZA 200906802 A ZA200906802 A ZA 200906802A ZA 200906802 A ZA200906802 A ZA 200906802A ZA 200906802 B ZA200906802 B ZA 200906802B
Authority
ZA
South Africa
Prior art keywords
bifidobacterium strains
probiotic bifidobacterium
probiotic
strains
bifidobacterium
Prior art date
Application number
ZA200906802A
Other languages
English (en)
Inventor
John Macsharry
Liam O'mahony
David O'sullivan
Barry Kiely
Original Assignee
Alimentary Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alimentary Health Ltd filed Critical Alimentary Health Ltd
Publication of ZA200906802B publication Critical patent/ZA200906802B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
ZA200906802A 2007-03-28 2009-09-30 Probiotic bifidobacterium strains ZA200906802B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90731007P 2007-03-28 2007-03-28

Publications (1)

Publication Number Publication Date
ZA200906802B true ZA200906802B (en) 2010-06-30

Family

ID=39748498

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200906802A ZA200906802B (en) 2007-03-28 2009-09-30 Probiotic bifidobacterium strains

Country Status (17)

Country Link
US (1) US8557233B2 (enExample)
EP (1) EP2134833B1 (enExample)
JP (1) JP5538209B2 (enExample)
KR (1) KR20100016012A (enExample)
CN (1) CN101688171B (enExample)
AU (1) AU2008231466B2 (enExample)
BR (1) BRPI0810087A2 (enExample)
CA (1) CA2682242A1 (enExample)
DK (1) DK2134833T3 (enExample)
GB (1) GB2465051B (enExample)
MX (1) MX2009010419A (enExample)
MY (1) MY146590A (enExample)
NZ (1) NZ580005A (enExample)
PL (1) PL2134833T3 (enExample)
RU (1) RU2473681C2 (enExample)
WO (1) WO2008117266A2 (enExample)
ZA (1) ZA200906802B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
KR20090127180A (ko) * 2007-03-28 2009-12-09 앨러멘터리 헬스 리미티드 프로바이오틱 비피도박테리움 스트레인
US7919250B2 (en) * 2007-07-31 2011-04-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
US20100074870A1 (en) * 2008-09-19 2010-03-25 Bristol-Myers Squibb Company Probiotic infant products
RU2546251C2 (ru) * 2009-11-11 2015-04-10 Алиментари Хелс Лимитед Пробиотический штамм бифидобактерий
AU2010317423C1 (en) * 2009-11-11 2015-01-22 Alimentary Health Limited A bifidobacterium strain
WO2011114916A1 (ja) * 2010-03-18 2011-09-22 森永乳業株式会社 貧血の予防又は治療用組成物
BR112013002667B1 (pt) 2010-08-04 2020-02-04 Thomas Julius Borody composições para transplante da flora intestinal e métodos para fazê-las e usá-las e dispositivos para administrá-las
EP3610881A1 (en) 2011-03-09 2020-02-19 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
IN2014DN07752A (enExample) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
KR101453982B1 (ko) * 2012-09-19 2014-10-28 주식회사 쎌바이오텍 과민성 대장 증후군 예방 또는 치료용 조성물
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
GB2535034A (en) 2013-07-21 2016-08-10 Whole Biome Inc Methods and systems for microbiome characterization, monitoring and treatment
CN103820357A (zh) * 2013-12-30 2014-05-28 上海交大昂立股份有限公司 一株长双歧杆菌及其防治食物过敏的功能
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
ES2658310T3 (es) 2014-12-23 2018-03-09 4D Pharma Research Limited Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
CN107949391B (zh) 2015-05-14 2021-11-09 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
PT3297644T (pt) 2015-05-22 2022-03-30 Univ Arizona State Métodos para tratar distúrbios do espetro do autismo e sintomas associados
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3307288T (pt) 2015-06-15 2019-10-17 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI759266B (zh) 2015-06-15 2022-04-01 英商4D製藥研究有限公司 包含細菌菌株之組合物之用途
MA55434B1 (fr) 2015-06-15 2022-02-28 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
KR20170032815A (ko) * 2015-09-15 2017-03-23 경희대학교 산학협력단 신규 유산균 및 퇴행성 뇌질환 또는 인지기능의 예방, 개선 또는 치료용 조성물
MA45287A (fr) * 2015-11-20 2018-08-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3386523B1 (en) 2015-12-11 2019-10-09 Alimentary Health Limited Bifidobacterium longum for treating obesity and associated metabolic disorders
PT3313423T (pt) 2016-03-04 2019-07-10 4D Pharma Plc Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN107043705A (zh) * 2016-12-30 2017-08-15 大连医科大学 用于建立临床营养菌种资源库的益生菌筛选方法
CA3052134C (en) * 2017-01-31 2023-01-03 University-Industry Cooperation Group Of Kyung Hee University Novel lactic acid bacteria and use thereof
EP3578637A4 (en) * 2017-01-31 2020-12-16 University - Industry Cooperation Group of Kyung Hee University NEW LACTIC BACTERIA AND THEIR USE
EP3589726A1 (en) * 2017-02-28 2020-01-08 Alimentary Health Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
ES2834950T3 (es) 2017-02-28 2021-06-21 Prec Group Limited Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmunitaria a la infección por virus respiratorio
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
WO2018187467A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (pd) and related disorders
RS61872B1 (sr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
WO2018218159A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
JP6840272B2 (ja) 2017-06-14 2021-03-10 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
RS63393B1 (sr) 2017-06-14 2022-08-31 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
MA51770A (fr) 2017-07-05 2020-05-13 Evelo Biosciences Inc Compositions et méthodes de traitement du cancer à l'aide de bifidobacterium animalis ssp. lactis
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP4154722A1 (en) * 2018-01-29 2023-03-29 PrecisionBiotics Group Limited A combination product for prophylaxis and treatment of irritable bowel syndrome
RU2670054C1 (ru) * 2018-04-24 2018-10-17 Федеральное государственное бюджетное учреждение науки Институт клеточного и внутриклеточного симбиоза Уральского отделения Российской академии наук Штамм бактерий Bifidobacterium bifidum ICIS-310 - продуцент ингибитора провоспалительного цитокина INF-γ
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
CN113164527A (zh) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
CN110959676B (zh) * 2018-09-30 2022-11-25 内蒙古伊利实业集团股份有限公司 一种含乳双歧杆菌的发酵乳制品及其应用
PE20221399A1 (es) 2019-07-19 2022-09-15 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales
EP4038185A1 (en) * 2019-09-30 2022-08-10 Sigma-Aldrich Co. LLC Modulation of microbiota compositions using targeted nucleases
WO2021242056A1 (ko) * 2020-05-28 2021-12-02 주식회사 바이오뱅크힐링 비피도박테리움 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023230318A1 (en) * 2022-05-27 2023-11-30 Texas Tech University System Novel vaccines for tuberculosis
CN115428954A (zh) * 2022-09-15 2022-12-06 北京三元食品股份有限公司 复合益生菌及发酵乳在制备用于辅助治疗hiv患者产品中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
ITBO20020564A1 (it) * 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
WO2004076615A2 (en) * 2003-02-27 2004-09-10 Bioneer A/S Immunomodulating probiotic compounds
RU2244745C2 (ru) * 2003-03-05 2005-01-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского Министерства здравоохранения Российской Федерации" Штамм bifidobacterium longum 379-ин, используемый для получения бактерийных препаратов, биологически активных добавок к пище, кисломолочных ферментированных и неферментированных пищевых продуктов, гигиенических и косметических средств
EP1481681A1 (en) * 2003-05-30 2004-12-01 Claudio De Simone Lactic acid bacteria combination and compositions thereof
JP5273695B2 (ja) * 2005-03-03 2013-08-28 株式会社明治 ビフィズス菌を有効成分とするアレルギー予防および／または治療剤

Also Published As

Publication number Publication date
MY146590A (en) 2012-08-30
GB0916986D0 (en) 2009-11-11
US20110020284A1 (en) 2011-01-27
PL2134833T3 (pl) 2016-09-30
EP2134833A2 (en) 2009-12-23
KR20100016012A (ko) 2010-02-12
US8557233B2 (en) 2013-10-15
CN101688171B (zh) 2013-03-27
AU2008231466B2 (en) 2013-05-23
GB2465051A (en) 2010-05-12
EP2134833B1 (en) 2016-03-09
CN101688171A (zh) 2010-03-31
DK2134833T3 (en) 2016-06-20
JP2010522552A (ja) 2010-07-08
GB2465051B (en) 2012-01-25
CA2682242A1 (en) 2008-10-02
HK1141555A1 (en) 2010-11-12
BRPI0810087A2 (pt) 2014-10-21
JP5538209B2 (ja) 2014-07-02
WO2008117266A3 (en) 2008-11-20
AU2008231466A1 (en) 2008-10-02
MX2009010419A (es) 2010-02-18
RU2473681C2 (ru) 2013-01-27
WO2008117266A2 (en) 2008-10-02
NZ580005A (en) 2012-03-30
RU2009136395A (ru) 2011-05-10

Similar Documents

Publication Publication Date Title
GB2460781B (en) Probiotic bifidobacterium strains
GB2465051B (en) Probiotic bifidobacterium strains
PL2498789T3 (pl) Probiotyczny szczep bifidobacterium
PL2352389T3 (pl) Bifidobacterium longum
ZA201202155B (en) Bifidobacterium longum and functional gi disorders
EP2323494B8 (en) Probiotic infant products
EP2323493B8 (en) Probiotic infant products
PL2823822T3 (pl) Szczep Bifidobakterium
DK2318513T3 (da) Ny probiotisk bifidobacterium longum
PL2485743T3 (pl) Szczepy Lactobacillus plantarum jako czynniki hipocholesterolemiczne
SG11201602868WA (en) Probiotic stabilization
PL2268792T3 (pl) Szczep lactobacillus rhamnosus
LT1996696T (lt) Termostabilūs loctobacillus kamienai
ZA201208977B (en) Probiotic strains for use in improving the enteric nervous system
ZA201007327B (en) Synbiotic mixture
PL380590A1 (pl) Preparat probiotyczny
GB0715936D0 (en) Mutant bacterium
AP2012006139A0 (en) Composition comprising strains of lactobacillus fermentum.
PT1820849E (pt) Novas estirpes de lactobacillus helveticus
PT1820850E (pt) Novas estirpes de lactobacillus helveticus
AP2008004650A0 (en) Novel enterococcus and streptococcus strains and bacteriocins
AU2006905424A0 (en) Probiotic lactobacillus strains
TWI349706B (en) Bacillus probiotics expression systems
PL380803A1 (pl) Nowy szczep Bifidobacterium longum
PL380804A1 (pl) Nowy szczep Lactobacillus rhamnosus